日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Efficacy and Safety of High-Dose Pioglitazone as Add-on Therapy in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Dapagliflozin and Metformin: Double-Blind, Randomized, Placebo-Controlled Trial

高剂量吡格列酮作为附加疗法治疗达格列净和二甲双胍控制不佳的2型糖尿病患者的疗效和安全性:双盲、随机、安慰剂对照试验

Hong, Jun Hwa; Han, Kyung Ah; Hwang, You-Cheol; Hong, Eun-Gyoung; Kim, Hae Jin; Lee, Chang Beom; Cho, Ho Chan; Won, Jong Chul; Kim, Hun-Sung; Kim, Eui-Hyun; Koh, Gwanpyo; Ahn, Kwang Hyun; Park, Kyong Soo

OTUB1 Modulates Ferroptosis by Regulating SLC7A11 Ubiquitination in Pancreatic β-Cells

OTUB1通过调节胰岛β细胞中SLC7A11的泛素化来调控铁死亡

Yoo, Soyeon; Kim, Dongkyu; Kim, Miyeon; Bae, Ju Young; Lee, Sang Ah; Kim, Eui Tae; Koh, Gwanpyo

Bardoxolone methyl inhibits ferroptosis through the Keap1‑Nrf2 pathway in renal tubular epithelial cells.

Bardoxolone methyl 通过 Keap1â€'Nrf2 通路抑制肾小管上皮细胞的铁死亡

Yoo Soyeon, Kim Miyeon, Bae Ju Young, Lee Sang Ah, Koh Gwanpyo

Bilateral adrenal adenomas with autonomous cortisol secretion from both glands and autonomous aldosterone secretion from the left adrenal: a case report

双侧肾上腺腺瘤伴双侧肾上腺自主分泌皮质醇及左侧肾上腺自主分泌醛固酮:病例报告

Han, Jung Eun; Yoo, Soyeon; Lee, Sang Ah; Koh, Gwanpyo

Enhancing Patient Outcomes: Prioritizing SGLT2is and GLP-1RAs in Diabetes with CVD

改善患者预后:在合并心血管疾病的糖尿病患者中优先使用SGLT2抑制剂和GLP-1受体激动剂

Koh, Gwanpyo

Study Design and Protocol for a Randomized Controlled Trial to Assess Long-Term Efficacy and Safety of a Triple Combination of Ezetimibe, Fenofibrate, and Moderate-Intensity Statin in Patients with Type 2 Diabetes and Modifiable Cardiovascular Risk Factors (ENSEMBLE)

评估依泽替米贝、非诺贝特和中等强度他汀类药物三联疗法治疗 2 型糖尿病合并可改变心血管危险因素患者的长期疗效和安全性的随机对照试验的研究设计和方案 (ENSEMBLE)

Kim, Nam Hoon; Lee, Juneyoung; Chon, Suk; Yu, Jae Myung; Jeong, In-Kyung; Lim, Soo; Kim, Won Jun; Song, Keeho; Cho, Ho Chan; Yu, Hea Min; Kim, Kyoung-Ah; Kim, Sang Soo; Lee, Soon Hee; Kim, Chong Hwa; Kwak, Soo Heon; Lee, Yong-Ho; Chung, Choon Hee; Lee, Sihoon; Jin, Heung Yong; Lee, Jae Hyuk; Koh, Gwanpyo; Kim, Sang-Yong; Kim, Jaetaek; Lee, Ju Hee; Kim, Tae Nyun; Jeon, Hyun Jeong; Lee, Ji Hyun; Jeon, Jae-Han; Yoo, Hye Jin; Kim, Hee Kyung; Park, Hyeong-Kyu; Nam-Goong, Il Seong; Hong, Seongbin; Ahn, Chul Woo; Yu, Ji Hee; Park, Jong Heon; Park, Keun-Gyu; Park, Chan Ho; Joung, Kyong Hye; Ryu, Ohk-Hyun; Park, Keun Yong; Hong, Eun-Gyoung; Cha, Bong-Soo; Won, Kyu Chang; Chung, Yoon-Sok; Kim, Sin Gon

Association of Glucagon to Insulin Ratio and Metabolic Syndrome in Patients with Type 2 Diabetes

型糖尿病患者胰高血糖素与胰岛素比率与代谢综合征的关系

Jisun Bang, Sang Ah Lee, Gwanpyo Koh, Soyeon Yoo

A double-blind, Randomized controlled trial on glucose-lowering EFfects and safety of adding 0.25 or 0.5 mg lobeglitazone in type 2 diabetes patients with INadequate control on metformin and dipeptidyl peptidase-4 inhibitor therapy: REFIND study

一项双盲、随机对照试验,旨在评估在二甲双胍和二肽基肽酶-4抑制剂治疗血糖控制不佳的2型糖尿病患者中,加用0.25或0.5 mg洛贝格列酮的降血糖效果和安全性:REFIND研究

Ryang, Soree; Kim, Sang Soo; Bae, Ji Cheol; Han, Ji Min; Kwon, Su Kyoung; Kim, Young Il; Nam-Goong, Il Seong; Kim, Eun Sook; Kim, Mi-Kyung; Lee, Chang Won; Yoo, Soyeon; Koh, Gwanpyo; Kwon, Min Jeong; Park, Jeong Hyun; Kim, In Joo

Current Status of Low-Density Lipoprotein Cholesterol Target Achievement in Patients with Type 2 Diabetes Mellitus in Korea Compared with Recent Guidelines

韩国2型糖尿病患者低密度脂蛋白胆固醇达标现状与最新指南的比较

Yun, Soo Jin; Jeong, In-Kyung; Cha, Jin-Hye; Lee, Juneyoung; Cho, Ho Chan; Choi, Sung Hee; Chun, SungWan; Jeon, Hyun Jeong; Kang, Ho-Cheol; Kim, Sang Soo; Ko, Seung-Hyun; Koh, Gwanpyo; Kwon, Su Kyoung; Lee, Jae Hyuk; Moon, Min Kyong; Noh, Junghyun; Park, Cheol-Young; Kim, Sungrae

The Change in Glucagon Following Meal Ingestion Is Associated with Glycemic Control, but Not with Incretin, in People with Diabetes

对于糖尿病患者来说,进餐后胰高血糖素的变化与血糖控制有关,但与肠促胰岛素无关

Soyeon Yoo, Dongkyu Kim, Gwanpyo Koh